482 related articles for article (PubMed ID: 18466288)
21. Serum alpha-fetoprotein level per tumor volume reflects prognosis in patients with hepatocellular carcinoma after curative hepatectomy.
Furihata T; Sawada T; Kita J; Iso Y; Kato M; Rokkaku K; Shimoda M; Kubota K
Hepatogastroenterology; 2008; 55(86-87):1705-9. PubMed ID: 19102374
[TBL] [Abstract][Full Text] [Related]
22. Angiopoietin-2 levels in the hepatic vein as a useful predictor of tumor invasiveness and prognosis in human hepatocellular carcinoma.
Kuboki S; Shimizu H; Mitsuhashi N; Kusashio K; Kimura F; Yoshidome H; Ohtsuka M; Kato A; Yoshitomi H; Miyazaki M
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e157-64. PubMed ID: 17931370
[TBL] [Abstract][Full Text] [Related]
23. Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma.
Daveau M; Scotte M; François A; Coulouarn C; Ros G; Tallet Y; Hiron M; Hellot MF; Salier JP
Mol Carcinog; 2003 Mar; 36(3):130-41. PubMed ID: 12619035
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins.
Wada H; Nagano H; Yamamoto H; Arai I; Ota H; Nakamura M; Damdinsuren B; Noda T; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Doki Y; Dono K; Nakamori S; Sakon M; Monden M
Oncol Rep; 2007 Oct; 18(4):801-9. PubMed ID: 17786339
[TBL] [Abstract][Full Text] [Related]
25. Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection.
Yang GH; Fan J; Xu Y; Qiu SJ; Yang XR; Shi GM; Wu B; Dai Z; Liu YK; Tang ZY; Zhou J
Oncologist; 2008 Nov; 13(11):1155-65. PubMed ID: 18997126
[TBL] [Abstract][Full Text] [Related]
26. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma.
Yuan RH; Jeng YM; Chen HL; Lai PL; Pan HW; Hsieh FJ; Lin CY; Lee PH; Hsu HC
J Pathol; 2006 Aug; 209(4):549-58. PubMed ID: 16739096
[TBL] [Abstract][Full Text] [Related]
27. Expression of CD147 as a significantly unfavorable prognostic factor in hepatocellular carcinoma.
Zhang Q; Zhou J; Ku XM; Chen XG; Zhang L; Xu J; Chen GS; Li Q; Qian F; Tian R; Wen N; Chen ZN
Eur J Cancer Prev; 2007 Jun; 16(3):196-202. PubMed ID: 17415090
[TBL] [Abstract][Full Text] [Related]
28. Gene and protein expression of RCAS1 in hepatocellular carcinoma.
Ikeguchi M; Hirooka Y; Kaibara N
Anticancer Res; 2003; 23(6D):4967-71. PubMed ID: 14981953
[TBL] [Abstract][Full Text] [Related]
29. The gene expression level of transforming growth factor-beta (TGF-beta) as a biological prognostic marker of hepatocellular carcinoma.
Ikeguchi M; Iwamoto A; Taniguchi K; Katano K; Hirooka Y
J Exp Clin Cancer Res; 2005 Sep; 24(3):415-21. PubMed ID: 16270528
[TBL] [Abstract][Full Text] [Related]
30. GADD45-alpha expression in cirrhosis and hepatocellular carcinoma: relationship with DNA repair and proliferation.
Gramantieri L; Chieco P; Giovannini C; Lacchini M; Treré D; Grazi GL; Venturi A; Bolondi L
Hum Pathol; 2005 Nov; 36(11):1154-62. PubMed ID: 16260267
[TBL] [Abstract][Full Text] [Related]
31. Preoperative plasma transcript AA454543 level is an independent prognostic factor for hepatocellular carcinoma after partial hepatectomy.
Cheung ST; Liu CL; Chow JP; Lee YT; Ip YC; Ho JC; Fan ST
Neoplasia; 2006 Sep; 8(9):696-701. PubMed ID: 16984726
[TBL] [Abstract][Full Text] [Related]
32. Decreased expression of inhibitor of growth 4 correlated with poor prognosis of hepatocellular carcinoma.
Fang F; Luo LB; Tao YM; Wu F; Yang LY
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):409-16. PubMed ID: 19208663
[TBL] [Abstract][Full Text] [Related]
33. Circulating messenger RNA of alpha-fetoprotein: a possible risk factor of recurrence after resection of hepatocellular carcinoma.
Jeng KS; Sheen IS; Tsai YC
Arch Surg; 2004 Oct; 139(10):1055-60. PubMed ID: 15492142
[TBL] [Abstract][Full Text] [Related]
34. Neural cadherin overexpression is a predictive marker for early postoperative recurrence in hepatocellular carcinoma patients.
Seo DD; Lee HC; Kim HJ; Min HJ; Kim KM; Lim YS; Chung YH; Lee YS; Suh DJ; Yu E; Chun SY
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1112-8. PubMed ID: 17944884
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?
Farinati F; Marino D; De Giorgio M; Baldan A; Cantarini M; Cursaro C; Rapaccini G; Del Poggio P; Di Nolfo MA; Benvegnù L; Zoli M; Borzio F; Bernardi M; Trevisani F
Am J Gastroenterol; 2006 Mar; 101(3):524-32. PubMed ID: 16542289
[TBL] [Abstract][Full Text] [Related]
36. Relation among p130Cas, E-cadherin and beta-catenin expression, clinicopathologic significance and prognosis in human hepatocellular carcinoma.
Guo C; Liu QG; Yang W; Zhang ZL; Yao YM
Hepatobiliary Pancreat Dis Int; 2008 Oct; 7(5):490-6. PubMed ID: 18842495
[TBL] [Abstract][Full Text] [Related]
37. ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma.
Lin SY; Pan HW; Liu SH; Jeng YM; Hu FC; Peng SY; Lai PL; Hsu HC
Clin Cancer Res; 2008 Aug; 14(15):4814-20. PubMed ID: 18676753
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma.
Poon RT; Chung KK; Cheung ST; Lau CP; Tong SW; Leung KL; Yu WC; Tuszynski GP; Fan ST
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4150-7. PubMed ID: 15217952
[TBL] [Abstract][Full Text] [Related]
39. Quantitation of alpha-fetoprotein messenger RNA for early detection of recurrent hepatocellular carcinoma: a prospective pilot study.
Schmilovitz-Weiss H; Stemmer SM; Liberzon E; Avigad S; Sulkes J; Belinki A; Kazatsker A; Ben-Ari Z
Cancer Detect Prev; 2006; 30(2):204-9. PubMed ID: 16638626
[TBL] [Abstract][Full Text] [Related]
40. Fascin expression in progression and prognosis of hepatocellular carcinoma.
Iguchi T; Aishima S; Umeda K; Sanefuji K; Fujita N; Sugimachi K; Gion T; Taketomi A; Maehara Y; Tsuneyoshi M
J Surg Oncol; 2009 Dec; 100(7):575-9. PubMed ID: 19697358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
